📣 VC round data is live. Check it out!

Perspective Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Perspective Therapeutics and similar public comparables like Beta Bionics, Medipost, IVF hartmann, Revenio Group and more.

Perspective Therapeutics Overview

About Perspective Therapeutics

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.


Founded

1983

HQ

United States

Employees

140

Financials (LTM)

Revenue: $716K
EBITDA: ($118M)

EV

$147M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Perspective Therapeutics Financials

Perspective Therapeutics reported last 12-month revenue of $716K and negative EBITDA of ($118M).

In the same LTM period, Perspective Therapeutics generated $716K in gross profit, ($118M) in EBITDA losses, and had net loss of ($111M).

Revenue (LTM)


Perspective Therapeutics P&L

In the most recent fiscal year, Perspective Therapeutics reported revenue of $884K and EBITDA of ($101M).

Perspective Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of (11403%) and net margin of (11665%).

See analyst estimates for Perspective Therapeutics
LTMLast FY202320242025202620272028
Revenue$716K$884K———
Gross Profit$716K————
Gross Margin100%————
EBITDA($118M)($101M)($39M)($78M)($101M)
EBITDA Margin(16552%)(11403%)———
EBIT Margin(16712%)(12847%)———
Net Profit($111M)($103M)($47M)($79M)($103M)
Net Margin(15565%)(11665%)———

Financial data powered by Morningstar, Inc.

Perspective Therapeutics Stock Performance

Perspective Therapeutics has current market cap of $414M, and enterprise value of $147M.

Market Cap Evolution


Perspective Therapeutics' stock price is $3.63.

Perspective Therapeutics share price decreased by 6.9% in the last 30 days, and increased by 41.2% in the last year.

Perspective Therapeutics has an EPS (earnings per share) of $-0.90.

See more trading valuation data for Perspective Therapeutics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$147M$414M-3.5%-6.9%-32.8%41.2%$-0.90

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Perspective Therapeutics Valuation Multiples

Perspective Therapeutics trades at 205.8x EV/Revenue multiple, and (1.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for Perspective Therapeutics

EV / Revenue (LTM)


Perspective Therapeutics Financial Valuation Multiples

As of May 20, 2026, Perspective Therapeutics has market cap of $414M and EV of $147M.

Perspective Therapeutics has a P/E ratio of (3.7x).

LTMLast FY202320242025202620272028
EV/Revenue205.8x166.6x———
EV/EBITDA(1.2x)(1.5x)(3.8x)(1.9x)(1.5x)
EV/EBIT(1.2x)(1.3x)(3.6x)(2.2x)(1.3x)
EV/Gross Profit205.8x————
P/E(3.7x)(4.0x)(8.9x)(5.2x)(4.0x)
EV/FCF—(1.5x)(3.9x)(2.0x)(1.5x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Perspective Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Perspective Therapeutics Margins & Growth Rates

Perspective Therapeutics decreased revenue by 50% but EBITDA grew by 30% in the last fiscal year.

In the most recent fiscal year, Perspective Therapeutics reported EBITDA margin of (11403%) and net margin of (11665%).

See estimated margins and future growth rates for Perspective Therapeutics

Perspective Therapeutics Margins

Last FY2026202720282029
Gross Margin—100%
EBITDA Margin(11403%)(29557%)
EBIT Margin(12847%)(29049%)
Net Margin(11665%)(28013%)
FCF Margin(10773%)—

Perspective Therapeutics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(50%)———
EBITDA Growth30%100%29%30%
EBIT Growth14%63%70%14%
Net Profit Growth21%70%30%21%
FCF Growth—91%31%—

Data powered by FactSet, Inc. and Morningstar, Inc.

Perspective Therapeutics Operational KPIs

Perspective Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.8M for the same period.

Access forward-looking KPIs for Perspective Therapeutics
LTMLast FY202620272028
Rule of 40(16592%)—
Bessemer Rule of X(16650%)—
Revenue per Employee—$0.0M
Opex per Employee—$0.8M
G&A Expenses to Revenue4208%3420%
R&D Expenses to Revenue12522%9527%
Opex to Revenue—12847%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Perspective Therapeutics Competitors

Perspective Therapeutics competitors include Beta Bionics, Medipost, IVF hartmann, Revenio Group, Standard BioTools, Vicenne, Kamada, Medistim, Medmix and Delcath Systems.

Most Perspective Therapeutics public comparables operate across Medical Devices, DeepTech, HealthTech and BioTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Beta Bionics2.3x2.0x(4.3x)(3.6x)
Medipost7.5x—(7.0x)—
IVF hartmann1.2x—7.6x—
Revenio Group3.2x2.8x11.4x11.1x
Standard BioTools(0.4x)(0.4x)0.6x0.8x
Vicenne3.3x—14.1x—
Kamada2.1x2.0x9.2x8.4x
Medistim5.7x5.5x17.9x18.3x

This data is available for Pro users. Sign up to see all Perspective Therapeutics competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Perspective Therapeutics

When was Perspective Therapeutics founded?Perspective Therapeutics was founded in 1983.
Where is Perspective Therapeutics headquartered?Perspective Therapeutics is headquartered in United States.
How many employees does Perspective Therapeutics have?As of today, Perspective Therapeutics has over 140 employees.
Who is the CEO of Perspective Therapeutics?Perspective Therapeutics' CEO is Johan M. Spoor.
Is Perspective Therapeutics publicly listed?Yes, Perspective Therapeutics is a public company listed on NYSE American.
What is the stock symbol of Perspective Therapeutics?Perspective Therapeutics trades under CATX ticker.
When did Perspective Therapeutics go public?Perspective Therapeutics went public in 2003.
Who are competitors of Perspective Therapeutics?Perspective Therapeutics main competitors include Beta Bionics, Medipost, IVF hartmann, Revenio Group, Standard BioTools, Vicenne, Kamada, Medistim, Medmix, Delcath Systems.
What is the current market cap of Perspective Therapeutics?Perspective Therapeutics' current market cap is $414M.
What is the current revenue of Perspective Therapeutics?Perspective Therapeutics' last 12 months revenue is $716K.
What is the current revenue growth of Perspective Therapeutics?Perspective Therapeutics revenue growth (NTM/LTM) is (39%).
What is the current EV/Revenue multiple of Perspective Therapeutics?Current revenue multiple of Perspective Therapeutics is 205.8x.
Is Perspective Therapeutics profitable?No, Perspective Therapeutics is not profitable.
What is the current EBITDA of Perspective Therapeutics?Perspective Therapeutics has negative EBITDA and is not profitable.
What is Perspective Therapeutics' EBITDA margin?Perspective Therapeutics' last 12 months EBITDA margin is (16552%).
What is the current EV/EBITDA multiple of Perspective Therapeutics?Current EBITDA multiple of Perspective Therapeutics is (1.2x).
How many companies Perspective Therapeutics has acquired to date?Perspective Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Perspective Therapeutics has invested to date?Perspective Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Perspective Therapeutics

Lists including Perspective Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial